NCT04982549 is a Phase 2 clinical trial of Durvalumab in Unresectable Stage III NSCLC, sponsored by Shandong Cancer Hospital and Institute.

Who is sponsoring NCT04982549?

NCT04982549 is sponsored by Shandong Cancer Hospital and Institute.

What drugs are being tested in NCT04982549?

Interventions in NCT04982549: Durvalumab, Carboplatin/ Paclitaxel, Pemetrexed/ Cisplatin, Pemetrexed/ Carboplatin, Radiation.

What condition does NCT04982549 study?

NCT04982549 studies Unresectable Stage III NSCLC.

Is NCT04982549 still recruiting?

NCT04982549 is currently status unknown. Last updated 6 August 2021.

Last reviewed 2021-08-06 · How we verify

NCT04982549

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Status unknown Phase 2 Last updated 6 August 2021

What this trial tests

Phase 2 trial testing Durvalumab in Unresectable Stage III NSCLC in 35 participants. Status unknown.

Timeline

21 January 2021

Primary endpoint
1 December 2022

1 March 2023

Quick facts

Lead sponsor	Shandong Cancer Hospital and Institute
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	21 January 2021
Primary completion	1 December 2022
Estimated completion	1 March 2023
Sites	2 locations across China

Drugs / interventions tested

Durvalumab — full drug profile →
Carboplatin/ Paclitaxel
Pemetrexed/ Cisplatin
Pemetrexed/ Carboplatin
Radiation

Conditions studied

Unresectable Stage III NSCLC — all drugs for Unresectable Stage III NSCLC →

Sponsor

Shandong Cancer Hospital and Institute

Who can join

18 and older, any sex, with Unresectable Stage III NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, multi-center, single arm study assessing the efficacy and safety of durvalumab given concurrently with platinum-based CRT (durvalumab + SoC CRT) in patients with locally advanced, unresectable NSCLC (Stage III).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives.
Césaire M, Montanari J, Curcio H, Lerouge D, et al · · 2022 · cited 35× · PMID 35740495 · DOI 10.3390/cancers14122829

Verify or expand the search:

Other trials of Durvalumab

Trials testing the same drug.

NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT07459634 — A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · Phase 2 · not yet recruiting

Other Shandong Cancer Hospital and Institute trials

Trials by the same sponsor.

NCT07408505 — Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer · NA · recruiting
NCT07403370 — Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis · recruiting
NCT07376174 — The Prognostic Impact of HER2 Expression in Non-Metastatic HER2-Positive Breast Cancer Treated With Dual HER2-Targeted T · recruiting
NCT07333274 — Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Adva · Phase 3 · recruiting
NCT07274774 — SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04982549 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shandong Cancer Hospital and Institute
Last refreshed: 6 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04982549.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing